JPWO2022072471A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022072471A5 JPWO2022072471A5 JP2023520341A JP2023520341A JPWO2022072471A5 JP WO2022072471 A5 JPWO2022072471 A5 JP WO2022072471A5 JP 2023520341 A JP2023520341 A JP 2023520341A JP 2023520341 A JP2023520341 A JP 2023520341A JP WO2022072471 A5 JPWO2022072471 A5 JP WO2022072471A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- subject
- sftpb
- cyfra21
- reporter molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 110
- 239000012472 biological sample Substances 0.000 claims 93
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 88
- 108010036226 antigen CYFRA21.1 Proteins 0.000 claims 88
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 68
- 201000005202 lung cancer Diseases 0.000 claims 68
- 208000020816 lung neoplasm Diseases 0.000 claims 68
- 239000000427 antigen Substances 0.000 claims 64
- 102000036639 antigens Human genes 0.000 claims 64
- 108091007433 antigens Proteins 0.000 claims 64
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 claims 63
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 claims 63
- NQNXERHVLXYXRO-UHFFFAOYSA-N Diacetylspermine Chemical compound Cl.Cl.CC(=O)NCCCNCCCCNCCCNC(C)=O NQNXERHVLXYXRO-UHFFFAOYSA-N 0.000 claims 62
- 206010056342 Pulmonary mass Diseases 0.000 claims 52
- 230000003211 malignant effect Effects 0.000 claims 39
- 239000000090 biomarker Substances 0.000 claims 37
- 230000002685 pulmonary effect Effects 0.000 claims 28
- 239000000523 sample Substances 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 18
- 238000003018 immunoassay Methods 0.000 claims 18
- 108010008629 CA-125 Antigen Proteins 0.000 claims 14
- 102000007269 CA-125 Antigen Human genes 0.000 claims 14
- 239000003153 chemical reaction reagent Substances 0.000 claims 13
- NWGZOALPWZDXNG-LURJTMIESA-N (2s)-5-(diaminomethylideneamino)-2-(dimethylamino)pentanoic acid Chemical compound CN(C)[C@H](C(O)=O)CCCNC(N)=N NWGZOALPWZDXNG-LURJTMIESA-N 0.000 claims 10
- KFEUJDWYNGMDBV-UHFFFAOYSA-N (N-Acetyl)-glucosamin-4-beta-galaktosid Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 KFEUJDWYNGMDBV-UHFFFAOYSA-N 0.000 claims 10
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 claims 10
- 239000004475 Arginine Substances 0.000 claims 10
- FONIWJIDLJEJTL-UHFFFAOYSA-N N(8)-acetylspermidine Chemical compound CC(=O)NCCCCNCCCN FONIWJIDLJEJTL-UHFFFAOYSA-N 0.000 claims 10
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 claims 10
- HESSGHHCXGBPAJ-UHFFFAOYSA-N N-acetyllactosamine Natural products CC(=O)NC(C=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O HESSGHHCXGBPAJ-UHFFFAOYSA-N 0.000 claims 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 10
- YDGMGEXADBMOMJ-UHFFFAOYSA-N asymmetrical dimethylarginine Natural products CN(C)C(N)=NCCCC(N)C(O)=O YDGMGEXADBMOMJ-UHFFFAOYSA-N 0.000 claims 10
- SKQLBVJMDVTJMX-UHFFFAOYSA-N diacetylspermidine Chemical compound CC(=O)N(C(C)=O)CCCCNCCCN SKQLBVJMDVTJMX-UHFFFAOYSA-N 0.000 claims 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 238000007619 statistical method Methods 0.000 claims 8
- 108091060302 Mir-320 Proteins 0.000 claims 7
- 108091062762 miR-21 stem-loop Proteins 0.000 claims 7
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims 7
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims 7
- 108091048308 miR-210 stem-loop Proteins 0.000 claims 7
- 238000005481 NMR spectroscopy Methods 0.000 claims 6
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 5
- 230000002494 anti-cea effect Effects 0.000 claims 4
- 238000005100 correlation spectroscopy Methods 0.000 claims 4
- 238000005160 1H NMR spectroscopy Methods 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 238000000870 ultraviolet spectroscopy Methods 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 238000000738 capillary electrophoresis-mass spectrometry Methods 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 claims 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 239000012474 protein marker Substances 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000004611 spectroscopical analysis Methods 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 238000013179 statistical model Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086865P | 2020-10-02 | 2020-10-02 | |
| US63/086,865 | 2020-10-02 | ||
| US202063106187P | 2020-10-27 | 2020-10-27 | |
| US63/106,187 | 2020-10-27 | ||
| PCT/US2021/052611 WO2022072471A1 (en) | 2020-10-02 | 2021-09-29 | Methods for the detection and treatment of lung cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023545017A JP2023545017A (ja) | 2023-10-26 |
| JP2023545017A5 JP2023545017A5 (https=) | 2024-10-07 |
| JPWO2022072471A5 true JPWO2022072471A5 (https=) | 2024-10-07 |
Family
ID=80950972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520341A Pending JP2023545017A (ja) | 2020-10-02 | 2021-09-29 | 肺がんの検出及び治療のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240159753A1 (https=) |
| EP (1) | EP4222287A4 (https=) |
| JP (1) | JP2023545017A (https=) |
| KR (1) | KR20230080442A (https=) |
| CA (1) | CA3163498A1 (https=) |
| WO (1) | WO2022072471A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110291397A (zh) * | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
| CA3165068A1 (en) | 2020-01-30 | 2021-08-05 | John E. Blume | Lung biomarkers and methods of use thereof |
| US12334190B2 (en) | 2021-03-31 | 2025-06-17 | PrognomIQ, Inc. | Multi-omic assessment using proteins and nucleic acids |
| GB2607436A (en) * | 2021-03-31 | 2022-12-07 | Prognomiq Inc | Multi-omic assessment |
| US12387508B2 (en) | 2021-09-10 | 2025-08-12 | PrognomIQ, Inc. | Direct classification of raw biomolecule measurement data |
| US12007397B2 (en) | 2021-09-13 | 2024-06-11 | PrognomIQ, Inc. | Enhanced detection and quantitation of biomolecules |
| WO2024107923A1 (en) * | 2022-11-17 | 2024-05-23 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
| EP4721103A2 (en) * | 2023-05-31 | 2026-04-08 | Board of Regents, The University of Texas System | Methods for the detection and treatment of lung cancer |
| GB202310137D0 (en) * | 2023-07-03 | 2023-08-16 | Belgian Volition Srl | Method for the detection of cancer |
| WO2025064345A2 (en) * | 2023-09-22 | 2025-03-27 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1610127B1 (en) * | 2003-03-11 | 2012-04-25 | CRC Inc. | N1,n12-diacetylspermine as tumor marker |
| CN102943108B (zh) * | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
| WO2012006632A2 (en) * | 2010-07-09 | 2012-01-12 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| WO2013154998A1 (en) * | 2012-04-09 | 2013-10-17 | Duke University | Serum biomarkers and pulmonary nodule size for the early detection of lung cancer |
| US9753037B2 (en) * | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| CA3198282A1 (en) * | 2015-06-26 | 2016-12-29 | Biomark Cancer Systems Inc. | Method of detecting lung cancer |
| CN109478231A (zh) * | 2016-04-01 | 2019-03-15 | 20/20基因系统股份有限公司 | 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物 |
| EP3361256A1 (en) * | 2017-02-08 | 2018-08-15 | Fundación para la Investigación Médica Aplicada | In vitro method for the diagnosis of lung cancer |
| CN110291397A (zh) * | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
-
2021
- 2021-09-29 KR KR1020237014384A patent/KR20230080442A/ko active Pending
- 2021-09-29 JP JP2023520341A patent/JP2023545017A/ja active Pending
- 2021-09-29 EP EP21876378.7A patent/EP4222287A4/en active Pending
- 2021-09-29 CA CA3163498A patent/CA3163498A1/en active Pending
- 2021-09-29 WO PCT/US2021/052611 patent/WO2022072471A1/en not_active Ceased
-
2023
- 2023-03-31 US US18/193,917 patent/US20240159753A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240361322A1 (en) | Lung cancer biomarkers | |
| JP2020510816A5 (https=) | ||
| TWI698639B (zh) | 前列腺抗原標準品及其用途 | |
| US20240027456A1 (en) | Lung cancer biomarkers | |
| KR20130119335A (ko) | 대상체에서 췌장암을 진단하기 위한 수단 및 방법 | |
| US20240151726A1 (en) | Diagnostic methods for liver disorders | |
| JP2018535433A (ja) | デンスブレストを有する女性における乳癌の検出のためのバイオマーカー | |
| US20230358764A1 (en) | Diagnostic methods for liver disorders | |
| JP7650538B2 (ja) | 血液由来エクソソームから見出した新規アルツハイマー病診断用バイオマーカー及びそれを用いたアルツハイマー病診断方法 | |
| US8053198B2 (en) | Diagnostic methods | |
| JPWO2022072471A5 (https=) | ||
| WO2015164616A1 (en) | Biomarkers for detection of tuberculosis | |
| Choi et al. | Evaluation of revisited fucosylated alpha-fetoprotein (AFP-L3) with an autoanalyzer μTAS in a clinical laboratory | |
| JP6421118B2 (ja) | 前立腺摘出術後の前立腺癌の再発の診断のための手段および方法 | |
| KR20230113742A (ko) | 난소암의 검출 및 치료를 위한 방법 | |
| CN120210363A (zh) | 用于诊断晚期鼻咽癌的生物标志物及其应用 | |
| KR101144324B1 (ko) | 대장암 예후진단용 단백질 마커 디펜신?５와 ｒｏｄ１단백질의 조합 및 이들 각각에 대한 항체를 포함하는 대장암 예후진단키트 | |
| Fan et al. | Serum Peptidome Patterns of Colorectal Cancer Based on Magnetic Bead Separation and MALDI‐TOF Mass Spectrometry Analysis | |
| US20210072245A1 (en) | Biomarkers for detection of breast cancer | |
| CN109154612B (zh) | 生物样品中磷酸化和非磷化形式的rkip的定量评估方法 | |
| US20220299514A1 (en) | Biomarkers of therapeutic responsiveness | |
| CN114200138A (zh) | 用于诊断和分期结直肠癌的生物标记物 | |
| US20250110132A1 (en) | Biomarkers for the determination of sample adequacy and lung cancer metastases | |
| WO2019162821A1 (en) | Immunological method and kit for in vitro diagnosis of tumour and/or inflammatory diseases | |
| Sorio et al. | Non‐invasive cancer detection: Strategies for the identification of novel cancer markers |